Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.

被引：4
|
作者：
Piha-Paul, Sarina Anne
Sachdev, Jasgit C.
Barve, Minal A.
LoRusso, Patricia
Szmulewitz, Russell Zelig
Patel, Sapna Pradyuman
McKee, Mark D.
Wolff, Johannes E.
Hu, Beibei
Sood, Anjla
Chen, Xiaotian
Wilson, Sarah C.
O'Neil, Bert H.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] HonorHealth Res Inst TGen, Scottsdale, AZ USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] AbbVie Inc, N Chicago, IL USA
[7] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2510
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma
    Yang, J.
    Yu, Y.
    Ren, X.
    Zhong, D.
    Sun, M.
    Wen, Q.
    Du, X.
    Liu, X.
    Shen, Z.
    Li, P.
    Ding, L.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1427 - S1427
  • [42] A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.
    Sangha, Randeep S.
    Jamal, Rahima
    Spratlin, Jennifer L.
    Kuruvilla, John
    Sehn, Laurie Helen
    Weickert, Michael
    Berthiaume, Luc G.
    Mackey, John Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.
    LoRusso, Patricia
    Shapiro, Geoffrey
    Pandya, Shuchi Sumant
    Kwak, Eunice Lee
    Jones, Cheryl
    Belvin, Marcia
    Musib, Luna C.
    de Crespigny, Alex
    McKenzie, Meghan
    Gates, Mary R.
    Chan, Iris Tan-Chi
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Phase 1, open-label, first-in-human study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors
    Shaheen, Montasser
    Markman, Ben
    Carducci, Michael
    Hurvitz, Sara
    Mahadevan, Daruka
    Kotasek, Dusan
    Goodman, Oscar
    Gamelin, Erick
    Chow, Vincent
    Juan, Gloria
    Rasmussen, Erik
    Friberg, Gregory R.
    Vogl, Florian D.
    Desai, Jayesh
    CANCER RESEARCH, 2016, 76
  • [45] A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors
    Baselga, J.
    De Jonge, M. J.
    Rodon, J.
    Burris, H. A., III
    Birle, D. C.
    De Buck, S. S.
    Demanse, D.
    Ru, Q. C.
    Goldbrunner, M.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias
    Garciaz, Sylvain
    Bories, Pierre
    Almeida, Leonor Lopez
    Boher, Jean-Marie
    Belanger, Coralie
    Recher, Christian
    Hermine, Olivier
    Vey, Norbert
    Launay, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias
    Garciaz, Sylvain
    Bories, Pierre
    Boher, Jean-Marie
    Hospital, Marie Anne
    Recher, Christian
    Saillard, Colombe
    Hicheri, Yosr
    Belanger, Coralie
    Monteiro, Renato
    Hermine, Olivier
    Launay, Pierre
    Vey, Norbert
    BLOOD, 2023, 142
  • [48] Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.
    Harb, Wael A.
    Adjei, Alex A.
    Beeram, Murali
    Pipas, J. Marc
    Chen, Sharon
    Valencia, Andrea
    Rimkunas, Victoria
    McClure, Ty
    Kearns, Jeffrey D.
    Nering, Rachel
    Lieu, Christopher Hanyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] FIRST-IN-HUMAN PHASE 1/2 STUDY OF THE FIRST-IN-CLASS SUMO-ACTIVATING ENZYME INHIBITOR TAK-981 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS OR RELAPSED/REFRACTORY LYMPHOMA: PHASE 1 RESULTS
    Dudek, Arkadiusz
    Juric, Dejan
    Dowlati, Afshin
    Vaishampayan, Ulka
    Assad, Hadeel
    Rodon, Jordi
    Chao, Bo
    Wang, Bingxia
    Gibbs, John
    Shinde, Vaishali
    Friedlander, Sharon
    Berger, Allison
    Ward, Christine
    Martinez, Alonzo
    Gharavi, Robert
    Gomez-Pinillos, Alejandro
    Proscurshim, Igor
    Olszanski, Anthony
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A505 - A506
  • [50] A first-in-human (FIH) phase I study of SAR12544, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results
    Angevin, Eric
    Spitaleri, Gianluca
    Hollebecque, Antoine
    De Pas, Tommaso
    Soria, Jean-Charles
    Harnols, Marzia
    Mazuir, Florent
    Assadourlan, Sylvie
    De Marinis, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345